From Research at med.fsu.edu Fri Sep 6 08:09:02 2019 From: Research at med.fsu.edu (Med Research) Date: Fri, 6 Sep 2019 12:09:02 +0000 Subject: Weekly Funding Opportunities Message-ID: <60E19361B71BE04F835C1FB3C18361BE019044A7DB@FSUCOM128.med.ad.fsu.edu> American Association of University Women: American Fellowships AAUW American Fellowships support women scholars who are completing dissertations, planning research leave from accredited institutions, or preparing research for publication. Applicants must be U.S. citizens or permanent residents. Candidates are evaluated on the basis of scholarly excellence; quality and originality of project design; and active commitment to helping women and girls through service in their communities, professions, or fields of research. Due November 1, 2019. Med-RA deadline to receive draft documents: October 21, 2019. Robert Wood Johnson Foundation's Systems for Action: Systems and Services Research for a Culture of Health Systems for Action (S4A) is a signature research program of the Robert Wood Johnson Foundation (RWJF) that helps to build the evidence base for a Culture of Health by rigorously testing new ways of connecting the nation's fragmented medical, social, and public health systems. Studies conducted through the S4A program test innovative mechanisms for aligning delivery and financing systems for medical, social, and public health services, with a focus on the effects of these mechanisms on health and health equity. S4A uses a wide research lens that includes and extends beyond medical care and public health to incorporate social service systems-such as housing, transportation; education; employment; food and nutrition assistance; child and family support; criminal and juvenile justice; and economic and community development. Research studies supported through S4A must: 1) focus on solutions to high-priority system alignment problems that involve medical, social, and public health services; 2) test the effectiveness of these solutions using rigorous scientific methods; and 3) engage stakeholders from medical, social, and public health systems in the design and conduct of the research, so that findings can be readily used in practice. This call for proposals will support studies that can be completed over a 36-month period with up to $500,000 in total funding from RWJF. Up to four awards will be selected for funding under this solicitation. Due November 6, 2019. Med-RA deadline to receive draft documents: October 24, 2019. Maternal and Child Health Field-Initiated Innovative Research Studies (FIRST) Program This notice announces the opportunity to apply for funding under the R40 Maternal and Child Health (MCH) Field-Initiated Innovative Research Studies (FIRST) Program. The purpose of the MCH FIRST Program is to advance the health and well-being of MCH populations by supporting innovative, applied, and translational intervention1 research studies on critical issues affecting MCH populations. The research findings of the R40 MCH FIRST Program should be generalizable to the broader U.S. population, and of regional and national significance. Findings from the research supported by the R40 MCH FIRST program are expected to: * Strengthen and expand topics addressed by the MCH Block Grant National Performance Domains (see Appendix C). For more background materials on the MCH Block Grant, see: https://urldefense.com/v3/__http://mchb.hrsa.gov/programs/titlevgrants/index.html__;!5Xm4_O-4tfk!g8qdlSqhSR0sedf7_sIes03_8prQL-9um12Ve9bY8Hki0ierein87g7BkrUVeeNTTaOUYXUZRcEUdhput2U$ . Researchers are encouraged to use holistic frameworks such as the life course health development (LCHD) and/or the social determinants of health (SDoH) in framing their study proposals. * Address HRSA's Maternal and Child Health Bureau (MCHB) Strategic Research Issues (see Appendix A) such as improving public health systems and infrastructure, reducing health inequalities, increasing quality of and access to care, and/or promoting the health of MCH populations. * Address HRSA's clinical priorities; namely, mental health, opioid abuse, childhood obesity, maternal mortality, and telehealth. Study findings will further develop the evidence base for the above clinical priority topics. * Address emerging research topics of regional and national significance that highlight new data, knowledge, evidence, and strategies for addressing the burden of diseases. HRSA expects each R40 MCH FIRST award recipient to complete the following major activities: * Conduct innovative applied or translational intervention research using rigorous scientific methodology * Recruit, track, and report study participants from diverse backgrounds to include diversity with regards to race/ethnicity, gender/sex, disability, geographic location, and socioeconomic status * Develop and submit a dissemination plan for the distribution of research findings and products to scientific, professional, and lay audiences. Dissemination activities include, but are not limited to, peer-reviewed articles, manuscripts, conference presentations, newsletter articles, webcasts, fact sheets, infographics, policy briefs, websites, and social media posts, as appropriate. Due November 12, 2019. Med-RA deadline to receive draft documents: October 28, 2019. Research Education: Short Courses on Alzheimer's Disease and Related Dementias for the Behavioral and Social Sciences (R25 Clinical Trial Not Allowed) The goal of this FOA is to support short courses geared to behavioral and social scientists who have existing expertise in aging research and can make research contributions in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) with additional knowledge about the disease and related research resources. Fields of behavioral and social science research relevant for this FOA are health economics, labor economics, health services research, healthcare policy, public policy, demography, sociology, social epidemiology, psychology, and social neuroscience. Priority areas of focus include, but are not limited to, the following: dementia care; dementia caregiver research; cognitive and dementia epidemiology; behavioral and social pathways of AD/ADRD; role of social, contextual, environmental, and institutional factors in AD/ADRD; early psychological changes preceding AD/ADRD onset; prevention of AD/ADRD; disparities in AD/ADRD or dementia-related outcomes; and research resources and methods for studying the determinants and impact of AD/ADRD. Due January 21, 2020. Med-RA deadline to receive draft documents: January 6, 2020. Biological Mechanisms of Metformin Effects on Aging and Longevity (R01 Clinical Trial Not Allowed) This FOA invites applications on novel studies of the molecular mechanisms underlying metformin's effects on aging and longevity. The goal of this FOA is to support applications that will lead to an in-depth understanding of the molecular mechanisms that determine the effects of metformin, either beneficial or detrimental, in relation to aging and longevity. Research supported by this FOA should lead to new insights on and better understanding of metformin's effects on aging and aging-related diseases. Due January 21, 2020. Med-RA deadline to receive draft documents: January 6, 2020. Explainable Artificial Intelligence for Decoding and Modulating Neural Circuit Activity Linked to Behavior (R01 Clinical Trial Optional) Explainable Artificial Intelligence (XAI) aims to provide strong predictive value along with mechanistic understanding of AI by combining machine learning techniques with effective explanatory techniques. This Funding Opportunity Announcement (FOA) solicits applications in the area of XAI applied to neuroscientific questions of encoding, decoding, and modulation of neural circuits linked to behavior. This FOA encourages collaborations between computationally and experimentally-focused investigators. This FOA seeks the development of machine learning algorithms that are able to mechanistically explain how experimental manipulations affect cognitive, affective, or social processing in humans or animals. Proof-of-concept applications aimed at improving the current state of the technology that uses XAI to provide unbiased, hierarchical explanations of causal relationships between complex neural and behavioral data are also appropriate. Due March 10, 2020; March 10, 2021; and March 10, 2022. Med-RA deadline to receive draft documents: February 26, 2020. HRSA Forecasts Maternal and Child Health Public Health Catalyst Program https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=319397__;!5Xm4_O-4tfk!g8qdlSqhSR0sedf7_sIes03_8prQL-9um12Ve9bY8Hki0ierein87g7BkrUVeeNTTaOUYXUZRcEUivCatP4$ Estimated post date: October 10 Estimated deadline: January 8 Autism Intervention Research Network on Physical Health (AIR-P) https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=319406__;!5Xm4_O-4tfk!g8qdlSqhSR0sedf7_sIes03_8prQL-9um12Ve9bY8Hki0ierein87g7BkrUVeeNTTaOUYXUZRcEU8-XwO3I$ Estimated post date: January 10 Estimated deadline: April 9 Autism Intervention Research Network on Behavioral Health (AIR-B) https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=319407__;!5Xm4_O-4tfk!g8qdlSqhSR0sedf7_sIes03_8prQL-9um12Ve9bY8Hki0ierein87g7BkrUVeeNTTaOUYXUZRcEU1s1w914$ Estimated post date: January 10 Estimated deadline: April 9 Children's Healthy Weight State Capacity Building Program https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=319401__;!5Xm4_O-4tfk!g8qdlSqhSR0sedf7_sIes03_8prQL-9um12Ve9bY8Hki0ierein87g7BkrUVeeNTTaOUYXUZRcEUZjkjOlc$ Estimated post date: January 17 Estimated deadline: April 16 Regional Genetics Networks https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=319403__;!5Xm4_O-4tfk!g8qdlSqhSR0sedf7_sIes03_8prQL-9um12Ve9bY8Hki0ierein87g7BkrUVeeNTTaOUYXUZRcEUb7r8UfA$ Estimated post date: November 14 Estimated deadline: January 12 Advances in Integrating Genetics into Clinical Care https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=319420__;!5Xm4_O-4tfk!g8qdlSqhSR0sedf7_sIes03_8prQL-9um12Ve9bY8Hki0ierein87g7BkrUVeeNTTaOUYXUZRcEUnKxUk4o$ Estimated post date: October 31 Estimated deadline: January 29 National Genetics Education and Family Support Center https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=319421__;!5Xm4_O-4tfk!g8qdlSqhSR0sedf7_sIes03_8prQL-9um12Ve9bY8Hki0ierein87g7BkrUVeeNTTaOUYXUZRcEUJKmBX_U$ Estimated post date: November 7 Estimated deadline: February 5 MCH Secondary Data Analysis Research Studies (MCH SDAR) https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=319409__;!5Xm4_O-4tfk!g8qdlSqhSR0sedf7_sIes03_8prQL-9um12Ve9bY8Hki0ierein87g7BkrUVeeNTTaOUYXUZRcEUWpX4cNM$ Estimated post date: November 9 Estimated deadline: February 7 Maternal and Child Health (MCH) Interdisciplinary Education in Pediatric Pulmonary Centers (PPCs) https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=319417__;!5Xm4_O-4tfk!g8qdlSqhSR0sedf7_sIes03_8prQL-9um12Ve9bY8Hki0ierein87g7BkrUVeeNTTaOUYXUZRcEUBpM1VSk$ Estimated post date: October 16 Estimated deadline: January 14 Centers of Excellence in Maternal and Child Health in Education, Science and Practice https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=319419__;!5Xm4_O-4tfk!g8qdlSqhSR0sedf7_sIes03_8prQL-9um12Ve9bY8Hki0ierein87g7BkrUVeeNTTaOUYXUZRcEUpQ4F024$ Estimated post date: October 10 Estimated deadline: January 8 Emergency Medical Services for Children Innovation and Improvement Center https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=319428__;!5Xm4_O-4tfk!g8qdlSqhSR0sedf7_sIes03_8prQL-9um12Ve9bY8Hki0ierein87g7BkrUVeeNTTaOUYXUZRcEUcqy7_DE$ Estimated post date: November 9 Estimated deadline: February 7 MCH Pregnancy-Related Care Research Network https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=319425__;!5Xm4_O-4tfk!g8qdlSqhSR0sedf7_sIes03_8prQL-9um12Ve9bY8Hki0ierein87g7BkrUVeeNTTaOUYXUZRcEU86cPQCA$ Estimated post date: January 24 Estimated deadline: April 23 MCH Pediatric Research Network Program https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=319427__;!5Xm4_O-4tfk!g8qdlSqhSR0sedf7_sIes03_8prQL-9um12Ve9bY8Hki0ierein87g7BkrUVeeNTTaOUYXUZRcEU3MOKz-8$ Estimated post date: January 24 Estimated deadline: April 23 Opioid Family Support Program (OFSP) https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=319617__;!5Xm4_O-4tfk!g8qdlSqhSR0sedf7_sIes03_8prQL-9um12Ve9bY8Hki0ierein87g7BkrUVeeNTTaOUYXUZRcEUaVP5ibg$ Estimated post date: November 4 Estimated deadline: February 3 To search for additional funding opportunities, please visit CoM's unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Wed Sep 11 16:14:48 2019 From: Research at med.fsu.edu (Med Research) Date: Wed, 11 Sep 2019 20:14:48 +0000 Subject: Weekly Funding Opportunities Message-ID: <60E19361B71BE04F835C1FB3C18361BE019044A9F6@FSUCOM128.med.ad.fsu.edu> Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. Standard dates apply. Expires May 8, 2021. Med-RA deadline to receive draft documents for October 2019 standard date: September 23, 2019. Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21 / R01 Clinical Trial Optional) R21 R01 These Funding Opportunity Announcements (FOAs) invite applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by these FOAs are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes. First due date for R21: October 16, 2019. First due date for R01: October 17, 2019. Then standard dates apply. Expires September 8, 2022. Med-RA deadline to receive draft documents for October 2019 due dates: October 3, 2019. Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03 / R21 / R01 Clinical Trial Optional) R03 R21 R01 These Funding Opportunity Announcements encourage research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery. First due date for R03 and R21: October 16, 2019. First due date for R01: October 17, 2019. Then standard dates apply. Expires September 8, 2022. Med-RA deadline to receive draft documents for October 2019 due dates: October 3, 2019. NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) This Funding Opportunity Announcement supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; innovative preclinical studies, including the use of new clinically-relevant models and imaging technologies, which could lead to first-in-human clinical trials, and therapeutic outcome disparities, including biomarkers or genetic/epigenetic signatures, among diverse racial/ethnic populations, including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical). Due October 18, 2019; February 20, 2020, June 19, 2020; October 20, 2020; February 19, 2021; June 21, 2021; October 20, 2021; February 22, 2022; and June 21, 2022. Med-RA deadline to receive draft documents for October 2019 due date: October 7, 2019. Neural Regulation of Cancer (R21 / R01 Clinical Trial Not Allowed) R21 R01 These Funding Opportunity Announcements encourage collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current understanding of the nervous system's contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors. Due October 21, 2019; May 27, 2020; October 21, 2020; May 27, 2021; October 21, 2021; and May 27, 2022. Med-RA deadline to receive draft documents for October 2019 due date: October 8, 2019. Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research (R21 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to address the needs of the maternal and pediatric HIV scientific community for research data translation and sharing. This initiative will support secondary data analyses using archived HIV/AIDS data and specimens to generate new research questions and findings relevant to the scientific mission and priorities of the NICHD, Maternal and Pediatric Infectious Disease Branch (MPIDB) and Office of AIDS Research (OAR). The goal of this initiative is to continue the encouragement of the scientific community to utilize HIV/AIDS archived data sets and specimen collections to answer important questions about the epidemiology, pathogenesis, treatment, clinical manifestations and complications of HIV/AIDS in maternal, pediatric and adolescent populations. Due November 1, 2019. Med-RA deadline to receive draft documents: October 21, 2019. Small Cell Lung Cancer (SCLC) Consortium: Biology, Therapy and Resistance (U01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) invites applications for research projects to join the Small-Cell Lung Cancer (SCLC) Consortium. Goals of the SCLC Consortium pertinent to this FOA are: 1) to learn the mechanistic and biological underpinnings of SCLC formation, progression and heterogeneity; 2) to investigate how molecular vulnerabilities could be used to develop targeted agents or combinations; and 3) to understand clinical resistance to drug and radiation therapy and its rapid development. Due November 12, 2019; March 11, 2020; November 12, 2020; March 11, 2021; November 12, 2021; and March 11, 2022. Med-RA deadline to receive draft documents for November 2019 due date: October 29, 2019. Trans-Agency Blood-Brain Interface Program (R61 / R33 - Clinical Trials Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to support high risk/high reward research on the blood/vascular component and regulation of the neurovascular-blood unit (a.k.a., Blood-Brain Barrier; BBB) in normal and pathological states to create enhanced/modified platforms that more closely model the human BBB. Research addressing vascular, hemostatic, hematopoietic, and/or immune cell interaction across the Blood-Brain Interface is of particular interest. This initiative will serve to stimulate the development of a new field of science and re-define the neurovascular unit to also include the blood/vascular component to develop the next generation of pre-clinical human cellular model systems of the human BBB to complement research currently based on animal models. Due December 2, 2019 and October 19, 2020. Med-RA deadline to receive draft documents for December 2019 due date: November 18, 2019. Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R21 Clinical Trial Not Allowed) R21 R01 The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical, preclinical and non-clinical research to determine the potential of MDSCs as a target for host-directed therapeutics for tuberculosis in the context of HIV co-infection, and to better understand the role of host-induced immunosuppression in the progression of Mycobacterium tuberculosis pathogenesis. Due January 8, 2020; January 8, 2021; and January 10, 2022. Med-RA deadline to receive draft documents for January 2020 due date: December 16, 2019. NSF's Accountable Institutions and Behavior (AIB) The Accountable Institutions and Behavior (AIB) Program supports basic scientific research that advances knowledge and understanding of issues broadly related to attitudes, behavior, and institutions connected to public policy and the provision of public services. Research proposals are expected to be theoretically motivated, conceptually precise, methodologically rigorous, and empirically oriented. Substantive areas include (but are not limited to) the study of individual and group decision-making, political institutions (appointed or elected), attitude and preference formation and expression, electoral processes and voting, public administration, and public policy. This work can focus on a single case or can be done in a comparative context, either over time or cross-sectionally. The Program does not fund applied research. The Program also supports research experiences for undergraduate students and infrastructural activities, including methodological innovations. In addition, we encourage you to examine the websites for the National Science Foundation's Law and Science (LS) and Security and Preparedness (SAP) programs. Due January 15, 2020 and August 17, 2020. Med-RA deadline to receive draft documents for January 2020 due date: January 2, 2020. Food as Medicine: Food Insecurity and HIV-related Comorbidities, Coinfections, and Complications within the Mission of the NIDDK (R01 Clinical Trial Optional) This funding opportunity announcement (FOA) seeks US domestic research projects that address how food insecurity effects HIV comorbidities, coinfections, and complications (CCCs) within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The approaches may address the pathways linking food insecurity and the development or exacerbation of CCCs; or they may evaluate the mechanisms whereby interventions that alleviate food insecurity improve CCCs. These mechanisms could be related to nutritional inadequacies or patient health-related behaviors. Due March 9, 2020. Med-RA deadline to receive draft documents: February 25, 2020. To search for additional funding opportunities, please visit CoM's unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Wed Sep 18 08:31:37 2019 From: Research at med.fsu.edu (Med Research) Date: Wed, 18 Sep 2019 12:31:37 +0000 Subject: Weekly Funding Opportunities Message-ID: <60E19361B71BE04F835C1FB3C18361BE019044ABAB@FSUCOM128.med.ad.fsu.edu> G. Harold and Leila Y. Mathers Foundation Grants Mathers Portal The mission of the Mathers Foundation is to advance knowledge in the life sciences by sponsoring scientific research that will benefit mankind. Basic scientific research, with potential translational application, is central to this goal, and fundamental to our operating principles. The Mathers Foundation funds research projects of up to 3 years in length at 10% IDC. Current areas of interest include immunology, microbiome, genomics, structural biology, cellular physiology, and neuroscience. Letters of intent are required and are accepted on a rolling basis. Med-RA deadline to receive draft documents: Ten business days prior to submission date. Fahs-Beck Fund for Research and Experimentation: Faculty/Post-Doctoral Grant Program (Fahs-Beck Fellows) Application Guidelines Grants of up to $20,000 are available to help support the research of faculty members or post-doctoral researchers affiliated with non-profit human service organizations in the United States and Canada. Areas of interest to the Fund are: studies to develop, refine, evaluate, or disseminate innovative interventions designed to prevent or ameliorate major social, psychological, behavioral or public health problems affecting children, adults, couples, families, or communities, or studies that have the potential for adding significantly to knowledge about such problems. The research for which funding is requested must focus on the United States or Canada or on a comparison between the United States or Canada and one or more other countries. Due November 1, 2019. Med-RA deadline to receive draft documents: October 21, 2019. Gerber Foundation Pediatric Research Grants The Foundation's mission focuses on infants and young children. Accordingly, priority is given to projects that improve the nutrition, care, and development of infants and young children from the first year before birth to three years of age. The Foundation is particularly interested in fresh approaches to solving common, everyday problems or emerging issues within our defined focus area. Projects should focus on issues faced by care providers that, when implemented, will improve the health, nutrition, and/or developmental outcomes for infants and young children. The board is particularly looking for practical solutions that can be easily and rapidly implemented on a broad scale with a predictable time frame to clinical application. Major target areas for research include: * New diagnostic tools that may be more rapid, more specific, more sensitive, less invasive * New treatment regimens that are improved or novel, less stressful or painful, more targeted, have less side effects, provide optimal dosing * Symptom relief * Preventative measures * Assessment of deficiencies or excesses (vitamins, minerals, drugs, etc.) * Risk assessment tools or measures for environmental hazards, trauma, etc. Note that the Foundation is looking for projects that will result in 'new' information, treatments or tools that will result in a change in practice. The board rarely funds projects that are focused on sharing current information with parents or caregivers (parent or provider educational programs). Concept paper due November 15, 2019. Med-RA deadline to receive draft documents: November 4, 2019. Preventive Health Service Use (R61 / R33 Clinical Trial Required) This Funding Opportunity Announcement (FOA) invites R61 / R33 applications to develop interventions for physician compliance with recommended prevention guidelines for older adults from the Centers for Disease Control and Prevention and the US Preventive Services Task Force. Specifically, applicants will develop electronic health record-based interventions to improve quality of care and health outcomes and reduce health disparities. This FOA will support an R61 pilot phase, which will allow researchers to use data analytics tools, including machine learning approaches, to establish the feasibility of identifying groups of patients not receiving recommended preventive care, and then create scalable, tailored interventions for these groups to help overcome barriers to uptake. If successful, researchers may transition to an R33 phase for implementation of pragmatic trials. All applicants are required to address health disparities. The transition from the R61 to the R33 phase of the award will be administratively reviewed for successful completion of the go/no-go criteria specified for the R61 phase. Due October 28, 2019. Med-RA deadline to receive draft documents: October 15, 2019. Resource-Related Research Projects for Development of Animal Models and Related Materials (R24 Clinical Trials Not-Allowed) The Office of Research Infrastructure Programs (ORIP) encourages grant applications aimed at developing, characterizing or improving animal models of human diseases; improving access to information about or generated from the use of animal models of human disease; or improving diagnosis and control of diseases of laboratory animals. The animal models and related materials developed must have broad application to multiple NIH Institutes or Centers (ICs) to align with the ORIP's trans-NIH mission. Applications must describe the need and potential impact of the proposed resources on broad research areas supported by multiple NIH ICs. Applications to develop models that relate strictly to a specific disease or a select area of research will not be considered acceptable. Projects that predominantly address the research interests of one NIH IC but are only peripherally related to the research interests of other Institutes and Centers will also not be acceptable for this FOA. Due October 28, 2019; January 27, 2020; May 27, 2020; September 28, 2020; January 26, 2021; May 26, 2021; September 28, 2021; January 26, 2022; and May 26, 2022. Med-RA deadline to receive draft documents for 2019 deadline: October 15, 2019. Social Epigenomics Research Focused on Minority Health and Health Disparities (R01-Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement is to support and accelerate human epigenomic investigations focused on identifying and characterizing the mechanisms by which social experiences at various stages in life, both positive and negative, affect gene function and thereby influence health trajectories or modify disease risk in racial/ethnic minority and other health disparity populations. Due November 6, 2019; November 6, 2020; and November 8, 2021. Med-RA deadline to receive draft documents for 2019 deadline: October 24, 2019. NSF: Cellular and Biochemical Engineering The Cellular and Biochemical Engineering (CBE) program is part of the Engineering Biology and Health cluster, which also includes: 1) the Biophotonics program; 2) the Biosensing program; 3) the Disability and Rehabilitation Engineering program; and 4) the Engineering of Biomedical Systems program. The Cellular and Biochemical Engineering program supports fundamental engineering research that advances understanding of cellular and biomolecular processes. CBE-funded research may lead to the development of enabling technology for advanced biomanufacturing in support of the therapeutic cell, biochemical, biopharmaceutical, and biotechnology industries. Fundamental to many research projects in this area is the understanding of how biomolecules, subcellular systems, cells, and cell populations interact, and how those interactions lead to changes in structure, function, and behavior. A quantitative treatment of problems related to biological processes is considered vital to successful research projects in the CBE program. The program encourages highly innovative and potentially transformative engineering research leading to novel bioprocessing and biomanufacturing approaches. The CBE program also encourages proposals that effectively integrate knowledge and practices from different disciplines while incorporating ongoing research into educational activities. Major areas of interest for the program include: * Metabolic engineering and synthetic biology for biomanufacturing, including the design of synthetic metabolic components and synthetic cells, * Quantitative systems biotechnology, * Microbiome structure, function, synthesis, and maintenance, * Protein and enzyme engineering, and * Single cell and population dynamics and modeling in the context of biomanufacturing. All proposals should include a description on the potential impact of proposed research on an associated biomanufacturing process. Proposals whose core innovation involves tissue engineering, organ culture, development of models of healthy or diseased physiology, or design and application of technologies focused on the diagnosis or treatment of disease should be submitted to the Engineering of Biomedical Systems program (CBET 5345). The duration of unsolicited proposal awards in CBET is generally up to three years. Single-investigator award budgets typically include support for one graduate student (or equivalent) and up to one month of principal investigator time per year (awards for multiple investigator projects are typically larger). Full proposals accepted anytime. Med-RA deadline to receive draft documents: Ten business days prior to submission date. NSF: Engineering of Biomedical Systems The Engineering of Biomedical Systems program is part of the Engineering Biology and Health cluster, which also includes: 1) the Biophotonics program; 2) the Biosensing program; 3) the Cellular and Biochemical Engineering program; and 4) the Disability and Rehabilitation Engineering program. The goal of the Engineering of Biomedical Systems (EBMS) program is to provide opportunities for creating fundamental and transformative research projects that integrate engineering and life sciences to solve biomedical problems and serve humanity in the long term. Projects are expected to use an engineering framework (for example, design or modeling) that supports increased understanding of physiological or pathophysiological processes. Projects must include objectives that advance both engineering and biomedical sciences. Projects may include: methods, models, and enabling tools applied to understand or control living systems; fundamental improvements in deriving information from cells, tissues, organs, and organ systems; or new approaches to the design of systems that include both living and non-living components for eventual medical use in the long term. The EBMS program supports fundamental and transformative research in the following areas of biomedical engineering: * Development of validated models (living or computational) of healthy and pathological tissues and organ systems that can support improved fundamental understanding of these systems or development and testing of medical interventions, * Design and validation of systems that integrate living and non-living components for improved understanding, diagnosis, monitoring, and treatment of disease or injury, * Advanced biomanufacturing of three-dimensional tissues and organs, and * Design and subsequent application of technologies and tools, including those that leverage an organism's microbiome, to investigate fundamental physiological and pathophysiological processes. Innovative proposals outside of these specific areas of biomedical engineering may be considered. However, prior to submission, it is strongly recommended that the Principal Investigator contacts the program director to avoid the possibility of the proposal being returned without review. Related programs also fund biomedical engineering research, and PIs are encouraged to examine these to find the appropriate program for submission. The long-term impact of the projects can be related to fundamental understanding of cell and tissue function in normal and pathological conditions, effective disease diagnosis and/or treatment, or improved health care delivery. The EBMS program does not support proposals having as their central theme drug design and delivery, the development of biomedical devices that do not include a living biological component, or the development of animal models of disease. For consideration by the EBMS program, proposals that advance the design of tools or technologies should also apply those technologies to advance knowledge in biomedical science. NSF does not support clinical trials; however, feasibility studies involving human volunteers may be supported if appropriate to the project objectives. The duration of unsolicited proposal awards in CBET is generally up to three years. Single-investigator award budgets typically include support for one graduate student (or equivalent) and up to one month of PI time per year (awards for multiple investigator projects are typically larger). Proposals accepted anytime. Med-RA deadline to receive draft documents: Ten business days prior to submission date. NSF: Biosensing The Biosensing program is part of the Engineering Biology and Health cluster, which also includes 1) the Biophotonics program; 2) the Cellular and Biochemical Engineering program; 3) the Disability and Rehabilitation Engineering program; and 4) the Engineering of Biomedical Systems program. The Biosensing program supports fundamental engineering research on devices and methods for measurement and quantification of biological analytes. Examples of biosensors include, but are not limited to, electrochemical/electrical biosensors, optical biosensors, plasmonic biosensors, and paper-based and nanopore-based biosensors. In addition to advancing biosensor technology development, proposals that address critical needs in biomedical research, public health, food safety, agriculture, forensic, environmental protection, and homeland security are highly encouraged. Proposals that incorporate emerging nanotechnology methods are especially encouraged. Areas of interest include: * Multiplex biosensing platforms that exceed the performance of current state-of-the-art devices * Novel transduction principles, mechanisms and sensor designs suitable for measurement in practical matrix and sample-preparation-free approaches, including error-free detection of pathogens and toxins in food matrices, waterborne pathogens, parasites, toxins, biomarkers in body fluids, neuron chemicals, and others that improve human condition * Biosensors that enable measurement of biomolecular interactions in their native states, transmembrane transport, intracellular transport and reactions, and other biological phenomena * Biosensing performance optimization for specific health applications such as point-of-care testing and personalized health monitoring * Miniaturization of biosensors for lab-on-a-chip and cell/organ-on-a-chip applications to enable measurement of biological properties and functions of cell/tissues in vitro * Biosensing systems with integration of artificial intelligence (AI) and machine learning * Biosensors that exploit quantum correlations to develop a suite of analytical tools that will have superior performance over ordinary classical biosensing technology * Biosensors that leverage unique electrical properties of biomolecules, such as DNA, proteins, cells, and the nervous system to develop miniaturized biomedical devices for modulating and characterization of biological species The Biosensors Program does not encourage proposals addressing surface functionalization and modulation of bio-recognition molecules, development of basic chemical mechanisms for biosensing applications, circuit design for signal processing and amplification, computational modeling, and microfluidics for sample separation and filtration. Medical imaging-based measurements are outside of the scope of the program interests. Proposals that rely heavily on descriptive approaches are given lower priority. Proposals for optimizing and/or utilizing established methods for specific applications should be directed to programs focused on the application of sensor technology. Innovative ideas outside of the above specific interest areas may be considered. However, prior to submission, it is recommended that the PI contact the Program Director to avoid the proposal being returned without review. Proposals accepted anytime. Med-RA deadline to receive draft documents: Ten business days prior to submission date. NSF: Disability and Rehabilitation Engineering The Disability and Rehabilitation Engineering program is part of the Engineering Biology and Health cluster, which also includes: 1) the Biophotonics program; 2) the Biosensing program; 3) the Cellular and Biochemical Engineering program; and 4) the Engineering of Biomedical Systems program. The Disability and Rehabilitation Engineering program supports fundamental engineering research that will improve the quality of life of persons with disabilities through: development of new technologies, devices, or software; advancement of knowledge regarding healthy or pathological human motion; or understanding of injury mechanisms. Research may be supported that is directed toward the characterization, restoration, rehabilitation, and/or substitution of human functional ability or cognition, or to the interaction between persons with disabilities and their environment. Areas of particular interest are neuroengineering and rehabilitation robotics. The program will also consider research in the areas of: new engineering approaches to understand healthy or pathological motion, both as a target for rehabilitation and as a means to characterize motion related to disability or injury; understanding injury at the tissue- or system-level such that interventions may be developed to reduce the impact of trauma and subsequent disability; or understanding the role of gut microbiota in modulating disability in the context of rehabilitation. Emphasis is placed on significant advancement of fundamental engineering knowledge that facilitates transformative outcomes. We discourage applications that propose incremental improvements. Innovative proposals outside of the above specific interest areas may be considered. However, prior to submission, it is recommended that the PI contact the Program Director to avoid the possibility of the proposal being returned without review. NSF does not support clinical trials; however, feasibility studies involving human volunteers may be supported if appropriate to the project objectives. The duration of unsolicited proposal awards in CBET is generally up to three years. Single-investigator award budgets typically include support for one graduate student (or equivalent) and up to one month of principal investigator time per year (awards for multiple investigator projects are typically larger). Proposals accepted anytime. Med-RA deadline to receive draft documents: Ten business days prior to submission date. NSF: Particulate and Multiphase Processes The Particulate and Multiphase Processes program is part of the Transport Phenomena cluster, which also includes 1) the Combustion and Fire Systems program; 2) the Fluid Dynamics program; and 3) the Thermal Transport Processes program. The goal of the Particulate and Multiphase Processes program is to support fundamental research on physico-chemical phenomena that govern particulate and multiphase systems, including flow of suspensions, drops and bubbles, granular and granular-fluid flows, behavior of micro- and nanostructured fluids, unique characteristics of active fluids, and self assembly/directed-assembly processes that involve particulates. The program encourages transformative research to improve our basic understanding of particulate and multiphase processes with emphasis on research that demonstrates how particle-scale phenomena affect the behavior and dynamics of larger-scale systems. Although proposed research should focus on fundamentals, a clear vision is required that anticipates how results could benefit important applications in advanced manufacturing, energy harvesting, transport in biological systems, biotechnology, or environmental sustainability. Collaborative and interdisciplinary proposals are encouraged, especially those that involve a combination of experiment with theory or modeling. Major research areas of interest in the program include: * Multiphase flow phenomena: Dynamics of particle/bubble/droplet systems, behavior of structured fluids (colloids/ferro-fluids), granular flows, rheology of multiphase systems, unique characteristics of active fluids, and novel approaches that relate micro- and nanoscale phenomena to macroscale properties and process-level variables. * Particle science and technology: Aerosols, production of particles and polymer-particle complexes with engineered properties, self-assembly, directed assembly, and template-directed assembly of particles into functional materials and devices. * Multiphase transport in biological systems: Analysis of physiological processes, applications of functionalized nanostructures in clinical diagnostics and therapeutics. * Interfacial transport: Dynamics of particles and macromolecules at interfaces, kinetics of adsorption and desorption of nanoparticles and surfactants and their spatial distributions at interfaces, complex molecular interactions at interfaces, formation of interfacial complexes that affect the dynamics of particles. Proposals accepted anytime. Med-RA deadline to receive draft documents: Ten business days prior to submission date. NSF: Biophotonics The Biophotonics program is part of the Engineering Biology and Health cluster, which also includes: 1) the Biosensing program; 2) the Cellular and Biochemical Engineering program; 3) the Disability and Rehabilitation Engineering program; and 4) the Engineering of Biomedical Systems program. The goal of the Biophotonics program is to explore the research frontiers in photonics principles, engineering and technology that are relevant for critical problems in fields of medicine, biology and biotechnology. Fundamental engineering research and innovation in photonics is required to lay the foundations for new technologies beyond those that are mature and ready for application in medical diagnostics and therapies. Advances are needed in nanophotonics, optogenetics, contrast and targeting agents, ultra-thin probes, wide field imaging, and rapid biomarker screening. Low cost and minimally invasive medical diagnostics and therapies are key motivating application goals. Research topics in this program include: * Macromolecule Markers: Innovative methods for labeling of macromolecules. Novel compositions of matter. Methods of fabrication of multicolor probes that could be used for marking and detection of specific pathological cells. Pushing the envelope of optical sensing to the limits of detection, resolution, and identification. * Low Coherence Sensing at the Nanoscale: Low coherence enhanced backscattering (LEBS). N-dimensional elastic light scattering. Angle-resolved low coherence interferometry for early cancer detection (dysplasia). * Neurophotonics: Studies of photon activation of neurons at the interface of nanomaterials attached to cells. Development and application of biocompatible photonic tools such as parallel interfaces and interconnects for communicating and control of neural networks. * Microphotonics and Nanophotonics: Development and application of novel nanoparticle fluorescent quantum-dots. Sensitive, multiplexed, high-throughput characterization of macromolecular properties of cells. Nanomaterials and nanodevices for biomedicine. * Optogenetics: Novel research in employing light-activated channels and enzymes for manipulation of neural activity with temporal precision. Utilizing nanophotonics, nanofibers, and genetic techniques for mapping and studying in real-time physiological processes in organs such as the brain and heart. Proposals accepted anytime. Med-RA deadline to receive draft documents: Ten business days prior to submission date. Office of the Assistant Secretary for Health Forecasts Pregnancy Prevention Research Grants Estimated post date: January 14, 2020 Estimated application due date: April 15, 2020 This funding opportunity is for new research, evaluation, and statistics grant projects that would make significant contributions to the mission of the organization and to the pregnancy prevention and family planning fields. Under this announcement, research and evaluation projects will be considered that encourage healthy behavior choices to delay the onset of sexual activity, reduce number of sexual partners, and if sexually active, encourage the use of preventative measure for STIs and pregnancy. These grants are for research that can be carried out within 1-2 years, such as secondary data analyses using existing program and evaluation data or administrative data. The purpose of these grants will be to allow the exploration of new questions in the area of promotion of healthy behavior to prevent pregnancy through analyses of existing data, new or advanced methods of secondary data analyses, or novel combination and integration of datasets. Grants under this announcement are not intended as a means to carry out data collection, ongoing data analyses or for the maintenance and distribution of data sets. Potential areas of investigation include: Identify factors that improve the efficiency, effectiveness, and quality of pregnancy prevention programs for adolescents or young adults, or reduce disparities, by age, gender, race/ethnicity, or setting. Identify and/or validate core program components or "active ingredients" essential for programs and practices to produce the desired outcomes. Identify specific characteristics of program models, participants, or program implementation associated with program impacts. Apply innovative methods or techniques from other disciplines that are novel to pregnancy prevention research such as network analysis, matching and distillation techniques, system dynamics modeling or geographic information systems, to address questions beyond the general effectiveness of pregnancy prevention programs. Med-RA deadline to receive draft documents: Ten business days prior to agency deadline. Research and Demonstration Grants to Prevent Teen Pregnancy Estimated post date: December 21, 2019 Estimated application due date: March 30, 2020 FY2020 funding is available to support new cooperative agreements to increase the number of effective programs to delay sexual initiation and prevent teen pregnancy and STIs by developing and evaluating new or innovative approaches. Funded grantees will develop and test new innovative interventions to prevent teen pregnancy and STIs and delay sexual initiation, and increase the number of programs available that are proven to delay sexual initiation and prevent teen pregnancy and STIs. Med-RA deadline to receive draft documents: Ten business days prior to agency deadline. To search for additional funding opportunities, please visit CoM's unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: